Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Chemours (CC) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 7.97% and -5.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Fantastic Earnings Charts to Finish the Week
by Tracey Ryniec
Earnings season is still rocking and rolling with some of the biggest companies in the world reporting this week.
Chemical Stock Earnings Slated on Nov 1: DWDP, CC, PAH & ICL
by Anindya Barman
Investors should check these chemical stocks before their quarterly results as the industry is expected to sustain the momentum in Q3.
What's in the Offing for Chemours (CC) in Q3 Earnings?
by Anindya Barman
While Chemours (CC) faces headwinds from raw material and distribution costs, it is likely to gain from higher demand and prices in Q3.
Chemours (CC) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Should Value Investors Consider Chemours (CC) Stock Now?
by Zacks Equity Research
Let's see if The Chemours Company (CC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The Key to Spotting a Value Trap
by Tracey Ryniec
Just because a stock sinks and has a low P/E, doesn???t mean it's a value stock. Learn how to spot a true value stock from a value trap.
Chemours (CC) Earnings, Revenues Trump Estimates in Q2
by Anindya Barman
Chemours (CC) topped expectations in Q2 on strong results across its business segments.
Chemours (CC) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 11.76% and 0.76%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cabot (CBT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot (CBT) is likely to see year-over-year revenue growth in Q3.
Mosaic (MOS) to Post Q2 Earnings: What's in the Cards?
by Anindya Barman
Strong expected segment performance is likely to support Mosaic's (MOS) Q2 results.
LyondellBasell's (LYB) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
LyondellBasell (LYB) expects to benefit from continued high operating rates in Q2. However, scheduled maintenance may weigh on results.
Chemical Stock Q2 Earnings Slated on Aug 2: DWDP, WLK & More
by Anindya Barman
Chemical companies are likely to gain from strategic actions and a favorable demand environment in Q2.
Westlake Chemical's (WLK) Q2 Earnings: Is a Beat Likely?
by Zacks Equity Research
Westlake Chemical (WLK) revenues are projected to increase on benefits from acquisition.
DowDuPont (DWDP) Q2 Earnings: Is Another Beat in Store?
by Anindya Barman
DowDuPont (DWDP) is likely to gain from continued strong demand, higher pricing and cost synergies in Q2.
Univar (UNVR) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Most segments of Univar (UNVR) are expected to witness a year-over-year improvement in Q2 revenues.
Will Higher Prices Drive CF Industries' (CF) Q2 Earnings?
by Zacks Equity Research
CF Industries' (CF) Q2 results are likely to benefit from higher prices across most segments.
U.S. Steel (X) Warms Up to Q2 Earnings: What's in the Cards?
by Anindya Barman
U.S. Steel (X) is likely to gain from higher steel pricing in the second quarter.
FMC Corp (FMC) Q2 Preview: Will the Earnings Streak Continue?
by Anindya Barman
Strong segment performance is expected to support FMC Corp.'s (FMC) earnings in Q2.
Will Sandbox Boost U.S. Silica's (SLCA) Earnings in Q2?
by Zacks Equity Research
U.S. Silica (SLCA) expects improved pricing and volumes for Sandbox.
Arconic (ARNC) Q2 Earnings Preview: What's in the Cards?
by Anindya Barman
Arconic (ARNC) is expected to gain from its cost reduction and productivity improvement actions in Q2.
Platform Specialty (PAH) Up 22% in 3 Months: Here's Why
by Zacks Equity Research
Platform Specialty's (PAH) shares ride on forecast-topping earnings performance and upbeat outlook.
Chemical Production on the Upswing: 5 Growth Stocks to Buy
by Anindya Barman
As the chemical industry's upturn is expected to continue, it will be a prudent idea to zero in on these stocks with compelling growth prospects.
Praxair Seals European Asset Sale Deal With Taiyo Nippon
by Zacks Equity Research
Praxair's (PX) agreement to divest majority of its European businesses to Taiyo Nippon Sanso drives a step toward Praxair-Linde merger.